Back to top
more

Apellis Pharmaceuticals (APLS)

(Delayed Data from NSDQ)

$49.86 USD

49.86
1,215,020

+1.93 (4.03%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $49.83 -0.03 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for APLS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Apellis Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 352 553 702 879 352
Receivables 206 8 10 0 0
Notes Receivable 0 0 0 0 0
Inventories 146 86 16 0 0
Other Current Assets 61 73 96 38 21
Total Current Assets 766 720 824 917 373
Net Property & Equipment 4 6 6 7 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 1 16 32 19 0
Total Assets 789 760 882 961 389
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 38 37 17 8 8
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 128 95 103 112 55
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 76 30 8 4 0
Total Current Liabilities 248 168 132 128 66
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 93 93 189 0 0
Long-Term Debt 0 0 0 359 143
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 242 316 345 254 135
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 594 590 683 756 355
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 3,036 2,480 1,857 1,131 616
Retained Earnings -2,837 -2,309 -1,657 -926 -581
Other Equity -4 -1 -2 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 195 170 199 205 34
Total Liabilities & Shareholder's Equity 789 760 882 961 389
Total Common Equity 195 170 199 205 34
Shares Outstanding 118.50 110.50 97.50 75.70 74.80
Book Value Per Share 1.64 1.54 2.04 2.70 0.46

Fiscal Year End for Apellis Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 352 454 617 766
Receivables NA 206 169 111 32
Notes Receivable NA 0 0 0 0
Inventories NA 146 99 103 85
Other Current Assets NA 61 75 61 71
Total Current Assets NA 766 797 893 954
Net Property & Equipment NA 4 5 5 6
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 1 1 1 1
Total Assets NA 789 818 916 979
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 38 18 28 31
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 128 117 98 71
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 76 45 44 30
Total Current Liabilities NA 248 186 175 139
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 93 93 93 93
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 296 290 322
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 594 586 570 567
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 3,036 2,982 2,955 2,900
Retained Earnings NA -2,837 -2,749 -2,609 -2,487
Other Equity NA -4 -1 -1 -1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 195 232 345 412
Total Liabilities & Shareholder's Equity NA 789 818 916 979
Total Common Equity 0 195 232 345 412
Shares Outstanding 120.50 118.50 118.50 117.70 116.10
Book Value Per Share 0.00 1.64 1.96 2.93 3.55